NCT06144749View on ClinicalTrials.gov

A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

February 15, 2025

Primary Completion Date

August 31, 2025

Study Completion Date

December 31, 2025

Conditions
Anemia, Sickle Cell
Interventions
DRUG

HBI-002

Oral liquid carbon monoxide drug product.

Trial Locations (2)

Unknown

RECRUITING

Cevaxin - The Panama Clinic, Panama City

RECRUITING

Hospital Pacífica Salud, Panama City

Sponsors
All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Hillhurst Biopharmaceuticals, Inc.

INDUSTRY

NCT06144749 - A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD) | Biotech Hunter | Biotech Hunter